Patents Assigned to Nektar Therapeutics
  • Polymer conjugates of therapeutic peptides
    Patent number: 9682153
    Abstract: The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.
    Type: Grant
    Filed: March 20, 2015
    Date of Patent: June 20, 2017
    Assignee: Nektar Therapeutics
    Inventors: Mary J. Bossard, Steven O. Roczniak, Harold Zappe, Yujun Wang, Ping Zhang, Dawei Sheng, C. Simone Jude-Fishburn, Elizabeth Louise Minamitani, Xiaofeng Liu, Haim Moskowitz, Dennis G. Fry, Cherie F. Ali, Christine Taylor Brew
  • Aerosolization device
    Patent number: 9675768
    Abstract: An aerosol transfer device for medical aerosol generators includes a body, fluidically coupled to a nebulizer and to a patient interface. An ambient air intake is formed into a lower body. The body is shaped and configured to optimize mixing of ambient air from the ambient air intake and the aerosol generated by the nebulizer, resulting in the formation of an aerosol plume having optimum characteristics for delivery of the aerosol to the patient's pulmonary system, such as the central or deep lung regions. The shape and dimensions of the body are further designed to minimize aerosol deposition, thus improving delivery efficiency.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: June 13, 2017
    Assignee: Nektar Therapeutics
    Inventors: James B. Fink, Nani P. Kadrichu
  • Oligomer-foscarnet conjugates
    Patent number: 9670235
    Abstract: The invention relates to (among other things) oligomer-foscarnet conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over previously administered un-conjugated foscarnet compounds.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: June 6, 2017
    Assignee: Nektar Therapeutics
    Inventors: Timothy A. Riley, Lin Cheng
  • Conjugates of an anti-TNF-alpha antibody
    Patent number: 9636412
    Abstract: Conjugates of an anti-TNF antibody and one or more nonpeptidic water soluble polymers are provided. Typically, the nonpeptidic water soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided, among other things, are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions to a patient.
    Type: Grant
    Filed: August 5, 2015
    Date of Patent: May 2, 2017
    Assignee: Nektar Therapeutics
    Inventors: Mary J. Bossard, Gayle Stephenson-Phillips
  • Oligomer-containing substituted aromatic triazine compounds
    Patent number: 9617228
    Abstract: The invention relates to (among other things) methods for treatment comprising administering oligomer-containing substituted aromatic triazine compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: April 11, 2017
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng
  • Particulate materials
    Patent number: 9616060
    Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogs thereof, or derivatives thereof.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: April 11, 2017
    Assignee: Nektar Therapeutics
    Inventors: Andreas Kordikowski, Stephen Ernest Walker, Peter York
  • N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides
    Patent number: 9616136
    Abstract: The invention relates to (among other things) N-optionally substituted aryl-2-oligomer-3-alkoxypropionamides and compositions comprising the same. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: April 11, 2017
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Wen Zhang
  • SYSTEMS AND METHODS FOR DRIVING NEBULIZERS
    Publication number: 20170072160
    Abstract: In various arrangements, a nebulizer element of a nebulizer may be energized with a drive signal. A phase offset of the drive signal may be measured. A phase delta may be determined. The phase delta may indicate a difference between a target phase offset and the measured phase offset. The target phase offset may indicate a non-zero target phase difference between the voltage of the drive signal and the current of the drive signal. A frequency of the drive signal may be changed to decrease the phase delta.
    Type: Application
    Filed: November 23, 2016
    Publication date: March 16, 2017
    Applicant: Nektar Therapeutics
    Inventors: Benjamin Morris Gordon, Steven David Gardner, Matthew James Hayes
  • Polymeric alpha-hydroxy aldehyde and ketone reagents and conjugation method
    Patent number: 9579392
    Abstract: Provided herein are polymeric ?-hydroxy aldehyde or ?-hydroxy ketone reagents which can be conjugated to amine-containing compounds to form stable conjugates in a single-step reaction. In selected embodiments, the polymeric reagent itself incorporates an internal proton-abstracting (basic) functional group, to promote more efficient reaction. The substituent is appropriately situated, via a linker if necessary, to position the group for proton abstraction, preferably providing a 4- or 5-bond spacing between the abstracting atom and the hydrogen atom on the ?-carbon. Also provided are methods of using the reagents and stable, solubilized conjugates of the reagents with biologically active compounds. In preferred embodiments, the polymeric component of the reagent or conjugate is a polyethylene glycol.
    Type: Grant
    Filed: November 24, 2015
    Date of Patent: February 28, 2017
    Assignee: Nektar Therapeutics
    Inventors: Sean M. Culbertson, Xiaoming Shen, Antoni Kozlowski, Samuel P. McManus
  • Compositions comprising two different populations of polymer-active agent conjugates
    Patent number: 9539337
    Abstract: Compositions comprising two different populations of polymer-active agent conjugates, wherein the weight average molecular weight of the polymers associated with each population is different, are provided. Also provided are methods preparing such compositions and methods for administering such compositions.
    Type: Grant
    Filed: December 10, 2004
    Date of Patent: January 10, 2017
    Assignee: Nektar Therapeutics
    Inventor: Mary J. Bossard
  • Oligomer-containing hydantoin compounds
    Patent number: 9540330
    Abstract: The invention relates to (among other things) oligomer-containing hydantoin compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits one or more advantages over corresponding compounds lacking the oligomer.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: January 10, 2017
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Stephanie Allums-Donald
  • Systems and methods for driving nebulizers
    Patent number: 9533118
    Abstract: In various arrangements, a nebulizer element of a nebulizer may be energized with a drive signal. A phase offset of the drive signal may be measured. A phase delta may be determined. The phase delta may indicate a difference between a target phase offset and the measured phase offset. The target phase offset may indicate a non-zero target phase difference between the voltage of the drive signal and the current of the drive signal. A frequency of the drive signal may be changed to decrease the phase delta.
    Type: Grant
    Filed: September 4, 2013
    Date of Patent: January 3, 2017
    Assignee: Nektar Therapeutics
    Inventors: Benjamin Morris Gordon, Steven David Gardner, Matthew James Hayes
  • Oligomer-opioid agonist conjugates
    Patent number: 9512135
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: December 6, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Multi-arm polymeric alkanoate conjugates
    Patent number: 9504755
    Abstract: Among other aspects, provided herein are multi-armed polymer conjugates comprising an alkanoate-linker, compositions comprising such conjugates, and related methods of making and administering the same. Methods of treatment employing such conjugates and related uses are also provided. The conjugates are prepared with high drug loading efficiencies.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: November 29, 2016
    Assignee: Nektar Therapeutics
    Inventors: Antoni Kozlowski, Samuel P. McManus, Jennifer Riggs-Sauthier, Xiaoming Shen, Wen Zhang
  • N-maleimidyl polymer derivatives
    Patent number: 9493609
    Abstract: The invention is directed to multi-functional N-maleimidyl polymer derivatives comprising a water soluble and non-peptidic polymer backbone having a terminal carbon, such as a poly(alkylene glycol), the terminal carbon of the polymer backbone being directly bonded to the nitrogen atom of a N-maleimidyl moiety without a linking group therebetween. The invention also provides two methods of preparing such linkerless N-maleimidyl polymer derivatives.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: November 15, 2016
    Assignee: Nektar Therapeutics
    Inventor: Xiaoming Shen
  • Von willebrand factor- and factor VIII-polymer conjugates having a releasable linkage
    Patent number: 9493544
    Abstract: The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: November 15, 2016
    Assignees: Nektar Therapeutics, Baxalta Incorporated, Baxalta GmbH
    Inventors: Mary J. Bossard, Gayle Stephenson, Zhihao Fang, Harold Zappe, Stacy Mitchell, Ping Zhang, Friedrich Scheiflinger, Peter Turecek, Juergen Siekmann, Katalin Varadi, Herbert Gritsch
  • Oligomer-amino acid conjugates
    Patent number: 9487473
    Abstract: The invention relates to (among other things) oligomer-amino acid conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated amino acid compounds.
    Type: Grant
    Filed: October 22, 2015
    Date of Patent: November 8, 2016
    Assignee: Nektar Therapeutics
    Inventors: Xuyuan Gu, Jennifer Riggs-Sauthier
  • Oligomer-opioid agonist conjugates
    Patent number: 9458166
    Abstract: The invention provides compounds that are chemically modified by covalent attachment of a water-soluble oligomer. A compound of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from those of the compound not attached to the water-soluble oligomer.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: October 4, 2016
    Assignee: Nektar Therapeutics
    Inventors: Jennifer Riggs-Sauthier, Bo-Liang Deng, Timothy A. Riley
  • Polymer-based compositions and conjugates of HIV entry inhibitors
    Patent number: 9446139
    Abstract: Provided herein are water-soluble polymer conjugates and polymer-based compositions of HIV entry inhibitors. Also provided are methods for synthesizing and administering such conjugates and compositions.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: September 20, 2016
    Assignee: Nektar Therapeutics
    Inventors: Michael D. Bentley, Xuan Zhao, Harold Zappe
  • Conjugates of small-interfering nucleic acids
    Patent number: 9433684
    Abstract: The present invention relates to conjugates of small-interfering nucleic acids (siNA). Compositions of siNA suited for administration to a patient are described. Methods for delivering the compositions are also described.
    Type: Grant
    Filed: August 19, 2009
    Date of Patent: September 6, 2016
    Assignee: Nektar Therapeutics
    Inventors: Samuel P. McManus, Timothy A. Riley, Sean M. Culbertson, Antoni Kozlowski, Dennis G. Fry, Xuejun Yuan, Dawei Sheng, Vidula R. Dixit